Modality
Gene Therapy
MOA
JAK1i
Target
C5
Pathway
Neuroinflam
FL
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
~Feb 2021
→ ~May 2022
Phase 3
Aug 2022
→ Apr 2031
Phase 3Current
NCT06091542
1,853 pts·FL
2022-08→2031-04·Not yet recruiting
1,853 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-115.0y awayPh3 Readout· FL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
Catalysts
Ph3 Readout
2031-04-11 · 5.0y away
FL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06091542 | Phase 3 | FL | Not yet recr... | 1853 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ARG-1250 | Argenx | Phase 2 | C5 |